Silymarin review found mixed marker changes and more adverse effects
In people with nonalcoholic fatty liver disease, silymarin-based regimens showed differing effects on laboratory markers, while pooled silymarin use was linked to more adverse effects.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Some silymarin regimens showed favorable changes in cholesterol or liver enzyme measurements, while other estimates remained statistically uncertain. The review also reported more adverse effects with silymarin use, most commonly gastrointestinal problems. Because interventions and controls varied, these findings do not establish a single overall benefit or show that laboratory changes improved patients' health.
The abstract does not map every result to a specific control or report treatment durations. Its liver-fat reduction descriptions lack enough detail for a clear quantitative interpretation.
Different regimens, different results
Silymarin was studied alone and alongside diets, medications, or lifestyle changes. Liver enzymes are blood measurements, rather than direct measures of how patients feel or function. Favorable changes were not consistent across all combinations or markers.
Uncertain effects and harms
Some cholesterol and liver enzyme estimates had uncertainty ranges that crossed zero, leaving their effects unresolved. The reported increase in adverse effects also matters when interpreting the favorable marker results; digestive problems were the most common harms.
The original publication
Efficacy of different interventions for nonalcoholic fatty liver disease: A meta-analysis of lifestyle modifications, silymarin, and medications.
Zhang Z, Li S, Sun J
Asia Pac J Clin Nutr · 2025
- PubMed ID
- 40738719
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.